

# PRODUCT PORTFOLIO



## WHO WE ARE?



OVER **70**  
FOREIGN MARKETS  
WHERE WE  
ARE PRESENT



**3**  
MANUFACTURING  
PLANTS



**8**  
REPRESENTATIVE  
OFFICES



NEARLY **900**  
PRODUCTS IN POLAND  
AND ABROAD



**19**  
THERAPEUTIC  
AREAS



**~2800**  
EMPLOYEES

## WHAT WE DO?

### Development of innovative generic drugs

- Unique combination drugs (FDC)
- New routes of administration
- New dosage forms
- Reduction of adverse events

## HOW WE DO IT?



OVER **200**  
RESEARCHERS



**256**  
PATENTS



**49**  
DEVELOPMENT  
PROJECTS



**91**  
TECHNICAL  
SOLUTIONS



**35 M EUR**  
FOR R&D PROJECTS  
IN 2024



**2**  
CO-DEVELOPMENTS

Early phase clinical trials

2022

**24**

2023

**19**

2024

**16**



Late phase clinical trials

**6**

**6**

**7**

# CARDIOLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
 <b>APIXABAN</b>	2,5 mg 5 mg	capsules	<b>Available</b>	Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
<b>BEMPEDOIC ACID</b>	180 mg	coated tablets	<b>Q3 2028</b>	Primary hypercholesterolaemia or mixed dyslipidaemia; ASCVD risk reduction.
<b>BEMPEDOIC ACID + EZETIMIBE</b>	180mg/10mg	coated tablets	<b>Q4 2028</b>	Primary hypercholesterolaemia or mixed dyslipidaemia; ASCVD risk reduction.
<b>BEMPEDOIC ACID + EZETIMIBE + ROSUVASTATIN</b>	180 mg/10 mg/10 mg 180 mg/10 mg/20 mg 180 mg/10 mg/30 mg 180 mg/10 mg/40 mg	coated tablets	<b>Q1 2029</b>	Hypercholesterolaemia or mixed dyslipidaemia; ASCVD risk reduction.
<b>CANDESARTAN + AMLODIPINE</b>	8 mg/5 mg 8 mg/10 mg 16 mg/5 mg 16 mg/10 mg	capsules	<b>Available</b>	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
<b>CANDESARTAN + AMLODIPINE + HCTZ</b>	16 mg/5 mg/12,5 mg 16 mg/10 mg/12,5 mg	capsules	<b>Available</b>	Treatment of hypertension, particularly in patients requiring multiple drugs to achieve blood pressure control.
<b>CILOSTAZOL</b>	50 mg 100 mg	tablets	<b>Available</b>	Treatment of intermittent claudication to improve walking distance in patients without pain.
<b>EPLERENONE</b>	25 mg 50 mg	coated tablets	<b>Available</b>	Treatment of heart failure post-myocardial infarction, and hypertension.
<b>FINERENONE</b>	10 mg 20 mg	coated tablets	<b>Q4 2027</b>	Treatment of chronic kidney disease (stage 3 and 4 with albuminuria), associated with type 2 diabetes in adults.
 <b>EZETIMIBE + ROSUVASTATIN</b>	10 mg/5 mg 10 mg/10 mg 10 mg/15 mg 10 mg/20 mg 10 mg/30 mg 10 mg/40 mg	tablets	<b>Available</b>	Treatment of hypercholesterolemia to lower total cholesterol and LDL cholesterol levels
<b>PERINDOPRIL TERT-BUTYLAMINE + AMLODIPINE</b>	4 mg/5 mg 4 mg/10 mg 8 mg/5 mg 8 mg/10 mg	tablets	<b>Available</b>	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
<b>RAMIPRIL + AMLODIPINE</b>	2,5 mg/5 mg 5 mg/5 mg 5 mg/10 mg 10 mg/5 mg 10 mg/10 mg	capsules	<b>Available</b>	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
<b>RAMIPRIL + AMLODIPINE + HCTZ</b>	5 mg/5 mg/25 mg 10 mg/5 mg/25 mg 5 mg/5 mg/12,5 mg 10 mg/10 mg/25 mg	capsules	<b>Available</b>	Treatment of hypertension in patients who require a combination of an ACE inhibitor, calcium channel blocker, and diuretic.
 <b>RAMIPRIL + AMLODIPINE + ROSUVASTATIN</b>	5 mg/5 mg/10 mg 10 mg/5 mg/10 mg 10 mg/10 mg/10 mg 5 mg/5 mg/20 mg 10 mg/5 mg/20 mg 10 mg/10 mg/20 mg	capsules	<b>Available</b>	Management of hypertension and hypercholesterolemia, particularly in patients at high risk of cardiovascular events.
<b>RAMIPRIL + BISOPROLOL</b>	2,5 mg/1,25 mg 2,5 mg/2,5 mg 5 mg/2,5 mg 5 mg/5 mg 10 mg/5 mg 10 mg/10 mg	capsules	<b>Available</b>	Treatment of hypertension, especially in patients where monotherapy is not sufficient.

<b>New</b> <b>RAMIPRIL + INDAPAMIDE SR</b>	5 mg/1,5 mg 10 mg/1,5 mg	modified release tablets	<b>Available</b>	Treatment of hypertension in patients who require a combination of an ACE inhibitor and a long-acting diuretic.
<b>RANOLAZINE</b>	375 mg 500 mg 750 mg	extended release tablets	<b>Available</b>	Treatment of chronic angina.
<b>RIVAROXABAN</b>	2,5 mg 10 mg 15 mg 20 mg	coated tablets	<b>Available</b>	Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of DVT and PE, and prevention of cardiovascular events in patients with coronary artery disease or peripheral artery disease.
<b>New</b> <b>RIVAROXABAN + ACETYLSALICYLIC ACID</b>	2,5 mg/50 mg	tablets	<b>Available</b>	Reduction of the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.
<b>ROSUVASTATIN</b>	5 mg 10 mg 15 mg 20 mg 30 mg 40 mg	coated tablets	<b>Available</b>	Treatment of hypercholesterolemia and prevention of cardiovascular disease
<b>ROSUVASTATIN + ACETYLSALICYLIC ACID</b>	5 mg/100 mg 10 mg/100 mg 20 mg/100 mg	capsules	<b>Available</b>	Prevention of cardiovascular events in patients with high cholesterol and a history of heart disease.
<b>ROSUVASTATIN + AMLODIPINE</b>	10 mg/5 mg 10 mg/10 mg 20 mg/5 mg 20 mg/10 mg	capsules	<b>Available</b>	Management of hypertension and hypercholesterolemia.
<b>New</b> <b>TELMISARTAN + ROSUVASTATIN</b>	40 mg/10 mg 40 mg/20 mg 80 mg/10 mg 80 mg/20 mg	coated tablets	<b>Available</b>	Management of hypertension and hypercholesterolemia.

## CENTRAL NERVOUS SYSTEM

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>New</b> <b>B1 + B6 + B12 VITAMIN COMPLEX</b>	150 mg/50 mg/0,2 mg	coated tablet	<b>Available</b>	Treatment and prevention of vitamin B1, B6, and B12 deficiencies; supportive therapy for neuralgia and neuritis; and enhancement of nerve function and regeneration
<b>BREXPIPIRAZOLE</b>	4 mg	coated tablet	<b>Q3 2028</b>	Schizophrenia (>13 y)
<b>CARIPRAZINE</b>	6 mg	coated tablet	<b>Q1 2027</b>	Schizophrenia
<b>DULOXETINE</b>	30 mg 60 mg	enteric-coated tablets	<b>Available</b>	Treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain
<b>OLANZAPINE</b>	5 mg 10 mg	tablets	<b>Available</b>	Treatment of schizophrenia and bipolar disorder; also used for the management of agitation associated with schizophrenia and bipolar I mania.
<b>OLANZAPINE ODT</b>	5 mg 10 mg 15 mg 20 mg	orodispersible tablets	<b>Available</b>	Treatment of schizophrenia and bipolar disorder; designed for patients who have difficulty swallowing tablets.

<b>PREGABALIN</b>	25 mg 50 mg 75 mg 100 mg 150 mg 200 mg 225 mg 300 mg	capsules	<b>Available</b>	Treatment of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury; management of fibromyalgia; adjunctive therapy for partial-onset seizures.
<b>New</b> <b>VORTIOXETINE HYDROBROMIDE</b>	5 mg 10 mg 15 mg 20 mg	tablets	<b>Available</b>	Treatment of major depressive disorder in adults.

## DIABETOLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>DAPAGLIFLOZIN</b>	5 mg 10 mg	tablets	<b>Q1 2026</b>	Treatment of type 2 diabetes mellitus to improve glycemic control, treatment of heart failure and chronic kidney disease.
<b>DAPAGLIFLOZIN + SITAGLIPTIN</b>	10 mg/50 mg 10 mg/100 mg	coated tablets	<b>Q2 2026</b>	Treatment of type 2 diabetes mellitus to improve glycemic control in adults when treatment with both dapagliflozin and sitagliptin is appropriate.
<b>New</b> <b>EMPAGLIFLOZIN</b>	10 mg 25 mg	coated tablets	<b>Available</b>	Treatment of type 2 diabetes mellitus to improve glycemic control, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
<b>New</b> <b>EMPAGLIFLOZIN + LINAGLIPTIN</b>	10 mg/5 mg 25 mg/5 mg	coated tablets	<b>Available</b>	Treatment of type 2 diabetes mellitus to improve glycemic control in adults when treatment with both empagliflozin and linagliptin is appropriate.
<b>LINAGLIPTIN</b>	5 mg	coated tablets	<b>Available</b>	Treatment of type 2 diabetes mellitus to improve glycemic control in adults, used as monotherapy or in combination with other antidiabetic agents.
<b>SITAGLIPTIN</b>	25 mg 50 mg 100 mg	coated tablets	<b>Available</b>	Treatment of type 2 diabetes mellitus to improve glycemic control in adults, used as monotherapy or in combination with other antidiabetic agents.
<b>SITAGLIPTIN + METFORMIN XR</b>	50 mg/500 mg 50 mg/1000 mg 100 mg/1000 mg	extended release tablets	<b>Available</b>	Treatment of type 2 diabetes mellitus to improve glycemic control in adults, when treatment with both sitagliptin and metformin is appropriate.

## GYNAECOLOGY AND UROLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>FINASTERIDE + TADALAFIL</b>	5 mg/5 mg	tablets	<b>Available</b>	Benign prostatic hyperplasia (BPH).
<b>FURAZIDIN</b>	50 mg 100 mg	tablets	<b>Available</b>	Treatment of bacterial urinary tract infections (UTIs).
<b>FURAZIDIN INTRAVAGINAL</b>	5 mg	vaginal tablets	<b>Q1 2028</b>	Treatment of bacterial vaginosis (BV).
<b>SILDENAFIL</b>	25 mg 50 mg 100 mg	coated tablets	<b>Available</b>	Treatment of erectile dysfunction.

<b>SOLIFENACIN + TAMSULOSIN OCAS®</b>	6 mg/0,4 mg	extended release tablets	<b>Available</b>	Treatment of moderate to severe storage symptoms (e.g., urgency, frequency, and incontinence) and voiding symptoms (e.g., weak stream, straining, and incomplete emptying) associated with benign prostatic hyperplasia (BPH) in men.
<b>TRANEXAMIC ACID</b>	500 mg 1000 mg	tablets	<b>Available</b>	Treatment and prevention of excessive bleeding, including heavy menstrual bleeding, hereditary angioedema, and bleeding associated with surgery, trauma, or dental procedures.

## ONCOLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>ABEMACICLIB</b>	50 mg 100 mg 150 mg 200 mg	coated tablets	<b>Q2 2028</b>	As monotherapy for HR <sup>+</sup> , HER <sup>2</sup> -advanced breast cancer after endocrine therapy and prior chemotherapy. In combination with fulvestrant for HR <sup>+</sup> , HER <sup>2</sup> -advanced breast cancer after endocrine therapy.
<b>ABIRATERONE</b>	500 mg	coated tablets	<b>Available</b>	Treatment of metastatic castration-resistant prostate cancer, in combination with prednisone or prednisolone.
<b>IBRUTINIB</b>	140 mg 280 mg 420 mg 560 mg	coated tablets	<b>Q1 2027</b>	Treatment of relapsed or refractory mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia.
<b>IMATINIB</b>	100 mg 400 mg	capsules	<b>Available</b>	Treatment of various types of cancer, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), and other malignancies with specific genetic mutations.
<b>RUXOLITINIB</b>	5 mg 10 mg 15 mg 20 mg	tablets	<b>Available</b>	Treatment of myelofibrosis (intermediate/high-risk), polycythaemia vera (resistant/intolerant to hydroxyurea), and steroid-refractory acute or chronic Graft-versus-Host Disease.

## OTHER THERAPY GROUPS

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>AZITHROMYCIN</b>	500 mg	coated tablets	<b>Available</b>	Treatment of various bacterial infections, including respiratory infections, skin infections, ear infections, and sexually transmitted diseases;
<b>DEXAMETHASONE</b>	4 mg 8 mg 20 mg	tablets	<b>Available</b>	Treatment of inflammation, allergic reactions, autoimmune conditions, and certain types of cancer; also used to manage cerebral edema, adrenal insufficiency, and as an antiemetic in chemotherapy.
<b>FLUDROCORTISONE</b>	0,1 mg	tablets	<b>Available</b>	Treatment of adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.




**RISEDRONATE SODIUM**35 mg  
75 mg

coated tablets

**Available**

Treatment and prevention of osteoporosis in postmenopausal women and men; treatment of Paget's disease of bone.

**OVER THE COUNTER**

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>CYTISINE</b>	1,5 mg	coated tablets	<b>Available</b>	Smoking cessation aid to reduce nicotine withdrawal symptoms and cravings associated with quitting smoking.
 <b>CYTISINE</b>	1,5 mg	oral solution (spray)	<b>Available</b>	Smoking cessation aid to reduce nicotine withdrawal symptoms and cravings associated with quitting smoking.
 <b>LEVODROPROPIZINE</b>	60 mg	orodispersible tablets	<b>Available</b>	Symptomatic treatment of cough in various respiratory conditions.
<b>MINOXIDIL</b>	5%	foam	<b>Available</b>	Treatment of androgenetic alopecia (pattern hair loss) in men and women.
 <b>OSELTAMIVIR</b>	75 mg	powder for oral solution	<b>Available</b>	Treatment and prevention of influenza A and B in adults and children; should be administered within 48 hours of symptom onset for maximum effectiveness.
<b>SILDENAFIL</b>	25 mg 50 mg	coated tablets	<b>Available</b>	Treatment of erectile dysfunction.

**RESPIRATORY**

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
<b>FLUTICASONE + UMECLIDINIUM + VILANTEROL</b>	92 µg/55 µg/22 µg	inhalation powder (multi-dose inhaler)	<b>Q4 2030</b>	Maintenance treatment of COPD.
<b>FLUTICASONE + VILANTEROL</b>	92 µg/22 µg 184 µg/22 µg	inhalation powder (multi-dose inhaler)	<b>Q1 2029</b>	Asthma (≥12 y); COPD with exacerbations.
<b>INDACATEROL + GLYCOPYRRONIUM + MOMETASONE</b>	114 µg/46 µg/136 µg	inhalation powder - hard capsules (single-dose inhaler)	<b>Q1 2031</b>	Asthma uncontrolled on high-dose ICS + LABA.
<b>INDACATEROL + MOMETASONE</b>	125 µg/62,5 µg 125 µg/127,5 µg 125 µg/260 µg	inhalation powder - hard capsules (single-dose inhaler)	<b>Q1 2031</b>	Asthma uncontrolled on ICS + LABA.
<b>UMECLIDINIUM + VILANTEROL</b>	55 µg/22 µg	inhalation powder (multi-dose inhaler)	<b>Q2 2029</b>	Maintenance bronchodilator for COPD.



Pienkow, M. Adamkiewicza 6A Str, 05-152 Czosnow, Poland  
tel.: +48 22 732 77 00, fax: +48 22 732 78 00  
e-mail: [LicenseOut@adamed.com](mailto:LicenseOut@adamed.com)  
[www.adamed.com](http://www.adamed.com)